Rein Therapeutics says first patient dosed in Renew Phase 2 trial of LTI-03

Rein Therapeutics (RNTX) announced that the first patient has been dosed in the Renew Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF. The Renew trial is a Phase 2 multi-center, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of LTI-03 in patients with IPF. Rein is collaborating with Iqvia (IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, on enrollment for the trial. Topline interim data from Renew is expected in the first half of 2026.